Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review

Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options

Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.

Richard Saynor
Richard Saynor • Source: Sandoz

The focus and strategy of Sandoz Inc. remain “unchanged” after parent company Novartis AG announced a strategic review of the business, Sandoz CEO Richard Saynor said in a recent interview.

Speaking shortly after Novartis announced the strategic review – that will “explore all options, ranging from retaining the business to...

More from Outlook Archive

More from Outlook